Immunic Q3 2020 Earnings Report
Key Takeaways
Immunic reported positive phase 2 data for IMU-838 in relapsing-remitting multiple sclerosis and is preparing end-of-phase 2 submission. They completed a successful common stock offering, raising $103.5 million. The company's cash position of approximately $133.2 million is expected to fund activities into the second half of 2022.
Released very positive Phase 2 data for IMU-838 in Relapsing-Remitting Multiple Sclerosis.
Company to submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021.
200 Patients Randomized in Phase 2 Trial of IMU-838 for the Treatment of Moderate COVID-19; Top-Line Data From Main Phase 2 Efficacy Analysis Expected in Q1 2021.
With Approximately $133 Million in Cash and Cash Equivalents, Immunic is Funded Through Key Value Inflection Points into the Second Half of 2022.
Immunic
Immunic
Forward Guidance
Immunic is focused on advancing its clinical programs for IMU-838, IMU-935, and IMU-856, with key milestones expected in the near term. The company anticipates submitting end-of-phase 2 meeting requests, initiating a phase 3 trial, and completing phase 1 trials.
Positive Outlook
- Preparation for, and initiation of, a phase 3 trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS).
- Phase 2 readouts of IMU-838 in patients with ulcerative colitis (UC).
- Phase 2 readouts of IMU-838 in patients with primary sclerosing cholangitis (PSC).
- Completion of the phase 1 trials of IMU-935.
- Completion of the phase 1 trials IMU-856.